Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEconomic evaluations of hepatitis B vaccination for developing countries
Expert Review of Vaccines, 06/23/09
Tu HAT et al. - It is concluded that for many developing countries implementation of universal immunization against HBV to reduce the level of endemicity of hepatitis B is an appropriate strategy, and probably cost effective in many settings. Given their limited financial resources, developing countries should properly plan how to achieve this.
Related Articles
Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B
Hepatology, 11/18/09
Relevance Score: 91%
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany
Journal of Clinical Virology, 11/16/09
Relevance Score: 91%
De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation
Liver Transplantation, 10/30/09
Relevance Score: 91%
Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression
Clinical Gastroenterology and Hepatology, 10/09/09
Relevance Score: 91%
FOXP3 Expression in Hepatitis C Virus-Specific CD4+ T Cells During Acute Hepatitis C
Gastroenterology, 10/06/09
Relevance Score: 91%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor